Skip to content
WeightLossDrugsGuide

Independent educational reference. Not a pharmacy, medical provider, or telehealth clinic — and not a substitute for medical advice.

Understanding Compounded GLP-1 Medications

Editorially reviewed by the editorial teamLast updated August 12, 2026Sources last verified August 12, 2026

Compounded GLP-1 products are not FDA-approved drugs. Compounded medications are prepared by pharmacies rather than manufactured and approved as finished products, which means the FDA has not reviewed them for safety, effectiveness, or quality. The FDA has issued specific warnings about compounded semaglutide and tirzepatide, including reports of dosing errors and products containing salt forms of the ingredients that are not the same as the approved drug.

Key facts

  • Compounded drugs are not FDA approved and are not "generics" — FDA-approved generics do not exist for semaglutide or tirzepatide.
  • The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality before they reach patients.
  • The FDA has warned about adverse events from compounded semaglutide, including dosing errors involving patients measuring their own doses.
  • The FDA has warned about products containing semaglutide or tirzepatide salt forms, which are different substances from the approved active ingredients.
  • Products sold without a prescription, or marketed as "research chemicals" or "research peptides," are outside the legitimate drug supply entirely.

What compounding is

Drug compounding is the practice of combining or altering ingredients to create a medication tailored to an individual patient — for example, when a patient has an allergy to an inactive ingredient in the commercial product. Compounded drugs have a legitimate role, but they occupy a different regulatory category from FDA-approved products.

The FDA does not approve compounded drugs. That means no agency has verified their safety, effectiveness, or quality before a patient uses them.

Why compounded GLP-1 products proliferated

When an FDA-approved drug is in shortage, federal law gives compounders more latitude to prepare copies. During GLP-1 shortages, large volumes of compounded semaglutide and tirzepatide entered the market. As shortages resolve, that latitude narrows — the regulatory situation here has changed repeatedly, so check current FDA guidance rather than relying on any static summary, including this page.

Specific FDA concerns

The FDA has publicly described adverse-event reports involving compounded semaglutide, including cases where patients or caregivers measured incorrect doses from multi-dose vials and syringes rather than using a prefilled pen.

The agency has also flagged products containing "semaglutide sodium" or "tirzepatide sodium" — salt forms that are different active ingredients from those in approved products, and that are not permitted in compounding on that basis.

How to protect yourself

Use a state-licensed pharmacy and a licensed prescriber. Never buy prescription medication from a seller that does not require a valid prescription.

Be skeptical of any product marketed as a "research peptide," sold "for research use only," or offered without a prescription. These are not legitimate routes to prescription medication, and we do not link to such sellers.

  • Verify pharmacy licensure through your state board of pharmacy
  • Confirm the prescriber is licensed in your state
  • Report suspected counterfeit or harmful products to the FDA MedWatch program

Medications discussed in this guide

Sources

  1. FDA: FDA’s concerns with unapproved GLP-1 drugs used for weight loss — FDA. Link last verified August 12, 2026.
  2. FDA: Human drug compounding overview — FDA. Link last verified August 12, 2026.
  3. FDA MedWatch adverse event reporting — FDA. Link last verified August 12, 2026.

Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.